10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
Atopic Dermatitis
DRUG: Pimecrolimus
The incidence rate of systemic malignancies in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream, 10 years of observation with 6-month reporting intervals
The incidence rate of lymphoma in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream, 10 years of observation with 6-month reporting intervals|The incidence rate of thyroid cancer in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream, 10 years of observation with 6-month reporting intervals|The incidence rate of cutaneous malignancy in pediatric subjects with atopic dermatitis who have been exposed to pimecrolimus 1% cream, 10 years of observation with 6-month reporting intervals
Registry study to examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.